Drug profile · INN
sibutramine hydrochloride
MERIDIA
sibutramine hydrochloride (MERIDIA) is a monoamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — sibutramine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
sibutramine hydrochloride (MERIDIA) is a monoamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Monoamine transporter inhibitor
Primary target: Monoamine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sibutramine hydrochloride?
sibutramine hydrochloride (MERIDIA) is a monoamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sibutramine hydrochloride?
MERIDIA is a marketed brand name for sibutramine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sibutramine hydrochloride?
sibutramine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.